Operates hospitals, clinics and pharmacies across India (post its Gulf business demerger), providing multi-specialty healthcare services.
Operates hospitals, clinics and pharmacies across India (post its Gulf business demerger), providing multi-specialty healthcare services.
In one line: India's smaller HCA Healthcare.
Moat: narrow (brand, installed base, regulatory licence). An established hospital network and brand trust in South India, though healthcare faces significant local/regional competition.
Headquarters: Kochi, India · Founded: 1987 · Employees: 22,413
Size Aster DM Quality Care (ASTERDM.NS) is an India Health Care company (Hospital/Nursing Management) with a market value of $6.83B, the 170th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹731.00 on 18 Nov 2026.
Performance Over six months the shares fell 2.4%, against +6.2% for the median peer and +3.8% for the India market (cap-weighted) — 7th lowest of 19 in its peer set.
Growth Revenue grew 50.5% over the last twelve months (peer median +8.0%); the operating margin is 15.6% (peer median 12.7%).
Valuation It trades at 63.5× forward earnings against a peer median of 32.8× (5th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 49% a year for seven years (Req g). Recent delivered growth is -12%, so the hurdle is +60 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.4 points below its cost of capital (12.7% WACC).
Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹65.1B | ₹46.4B | ₹41.4B | ₹37.0B | ₹29.9B |
| Revenue growth | — | +12% | +12% | +24% | — |
| Gross profit | ₹20.8B | ₹10.8B | ₹9.04B | ₹7.27B | ₹5.20B |
| EBITDA | ₹13.7B | ₹9.25B | ₹7.81B | ₹5.94B | ₹4.61B |
| Net income | ₹4.71B | ₹3.88B | ₹53.8B | ₹1.29B | ₹4.25B |
| Free cash flow | n/a | ₹2.01B | ₹867M | -₹8.48B | ₹9.70B |
| Capital expenditure | n/a | ₹4.78B | ₹3.57B | ₹8.06B | ₹8.48B |
| Total debt | ₹59.4B | ₹22.2B | ₹20.2B | ₹13.8B | ₹57.0B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Aster DM Quality Care ASTERDM.NS | $6.83B | -2% | +50% | 16% | 63.5× | 48.6% |
| Fortis Healthcare FORTIS.NS | $6.40B | -17% | +18% | 17% | 48.5× | 42.5% |
| Apollo Hospitals Enterprise APOLLOHOSP.NS | $13.6B | +10% | +19% | 12% | 51.0× | 33.3% |
| Max Healthcare Institute MAXHEALTH.NS | $10.6B | -4% | +15% | 21% | 55.2× | 45.3% |
| Narayana Hrudayalaya NH.NS | $4.13B | 0% | +71% | 13% | 34.2× | 31.2% |
| Krishna Institute of Medical Sciences KIMS.NS | $3.41B | +2% | +35% | 11% | 81.9× | n/a |
| Global Health MEDANTA.NS | $4.13B | +16% | +26% | 17% | 50.4× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ASTERDM.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +9.6% | +6.7% | 7th highest of 20 |
| 6-month return | -2.4% | +6.2% | 7th lowest of 19 |
| Distance from 52-week high | -18.0% | -13.7% | 9th lowest of 20 |
| Revenue growth (TTM) | +50.5% | +8.0% | 2nd highest of 20 |
| Operating margin | 15.6% | 12.7% | 7th highest of 20 |
| Forward P/E | 63.5× | 32.8× | 5th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 48.6% | 12.4% | most demanding of 18 |
| Growth delivered (Del g) | -11.6% | +9.7% | lowest of 18 |
| Hurdle (Req g minus delivered) | +60.2 pp | +3.4 pp | most demanding of 18 |
| ROIC minus cost of capital | -7.4 pp | +0.5 pp | 2nd lowest of 20 |
| EV / EBITDA | 50.3× | 19.1× | most expensive of 17 |
| Net debt / EBITDA | 2.7× | 2.2× | 8th most indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Aster DM Quality Care ASTERDM.NS | India | $6.83B | -2% | +50% | 16% | 63.5× | 48.6% | -11.6% |
| Chemed CHE | United States | $7.12B | +24% | +5% | 14% | 20.2× | 3.3% | +4.0% |
| Fortis Healthcare FORTIS.NS | India | $6.40B | -17% | +18% | 17% | 48.5× | 42.5% | +17.9% |
| PACS PACS | United States | $7.35B | +25% | +11% | 8% | 17.5× | 7.5% | +29.7% |
| Ramsay Health Care RHC.AX | Australia | $8.31B | +41% | +4% | 5% | 31.4× | 14.0% | +8.3% |
| Manipal Health Enterprises MANIPALHOS.NS | India | $9.69B | n/a | +25% | 19% | 66.5× | 32.9% | +28.8% |
| Max Healthcare Institute MAXHEALTH.NS | India | $10.6B | -4% | +15% | 21% | 55.2× | 45.3% | +27.2% |
| Universal Health Services UHS | United States | $10.7B | +13% | +8% | 11% | 8.3× | -1.8% | +8.5% |
| Narayana Hrudayalaya NH.NS | India | $4.13B | 0% | +71% | 13% | 34.2× | 31.2% | +25.0% |
| Global Health MEDANTA.NS | India | $4.13B | +16% | +26% | 17% | 50.4× | n/a | n/a |
| Surgery Partners SGRY | United States | $3.53B | +100% | +2% | 13% | 77.2× | 15.6% | +12.2% |
| Apollo Hospitals Enterprise APOLLOHOSP.NS | India | $13.6B | +10% | +19% | 12% | 51.0× | 33.3% | +19.0% |
| Krishna Institute of Medical Sciences KIMS.NS | India | $3.41B | +2% | +35% | 11% | 81.9× | n/a | n/a |
| National HealthCare NHC | United States | $3.16B | +1% | +6% | 0% | n/a | 6.4% | +9.7% |
| Topchoice Medical 600763.SS | China | $2.33B | -12% | +7% | 26% | 24.8× | 12.4% | +6.9% |
| Tenet Healthcare THC | United States | $21.6B | +45% | +6% | 17% | 13.4× | -1.4% | +3.9% |
| Brookdale Senior Living BKD | United States | $2.06B | -36% | -8% | 6% | 482.6× | 19.3% | -1.4% |
| Ardent Health ARDT | United States | $2.03B | +52% | +2% | 5% | 11.9× | -1.7% | +8.7% |
| Extendicare EXE.TO | Canada | $1.91B | -16% | +36% | 9% | 19.3× | 10.8% | +8.5% |
| Huaxia Eye Hospital 301267.SZ | China | $1.78B | -18% | +2% | 15% | 23.5× | 2.1% | +10.4% |